Clinical efficacy of Xuanfei Huazhuo prescription in treatment of 223 patients with Omicron COVID-19 in Gansu Province

OBJECTIVE To evaluate the clinical effect of Xuanfei Huazhuo prescription combined with Western medicine on treatment of Omicron COVID-19 in Gansu Province. METHODS A total of 223 patients with Omicron COVID-19 who were treated in the Second People's Hospital of Lanzhou, Gansu Province from Mar 6, 2022 to Apr 30,2022 and were randomly divided into the study group with 103 cases and the control group with 120 cases. The study group was treated with the Xuanfei Huazhuo prescription combined with Western medicine, while the control group was only treated with Western medicine. The laboratory test indexes, absorption rates of pulmonary lesions and length of hospital stay were compared between the two groups of patients, and the clinical effect of Xuanfei Huazhuo prescription was evaluated. RESULTS The levels of white blood cell (WBC), C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Crea) , D-dimer and fibrinogen (FIB) of the study group were significantly lower after the treatment than before the treatment (P＜0.05), while the levels of lymphocytes, neutrophils and platelets were significantly higher after the treatment than before the treatment (P＜0.05). After the treatment, the levels of lymphocytes and platelets of the study group were higher than those of the control group, while the levels of WBC, CRP and IL-6 of the study group were significantly lower than those of the control group (P＜0.05). There was no significant difference in the absorption rate of pulmonary lesions between the two groups. The positive rate of serum immunoglobin (Ig) G antibody of the study group was significantly higher after the nucleic acid was tested negative than at the admission to hospital (P＜0.05). The length of hospital stay of the study group was significantly shorter than that of the control group (P＜0.05). CONCLUSION The combined therapy of Xuanfei Huazhuo prescription with Western medicine may alleviate the inflammation of Omicron COVID-19, promote the absorption of pulmonary lesions, and shorten the length of hospital stay, with the safety high.